AgingResearch.NewsJoin free

Libra Therapeutics

CompanyUnited States

Libra Therapeutics develops 3 assets, the furthest preclinical (TRPML1 in Alzheimer's disease). Mostly small molecule acting on C9ORF72; based in the United States.

3
Assets
Furthest stage
Preclinical
Raised
US$29m
0
Trials
0
Signals

Pipeline

3

  • TRPML1

    Activates TRPML1 to enhance autophagic removal of toxic aggregates and protect neuronal health.

    Preclinical, Small molecule, Alzheimer's disease, amyotrophic lateral sclerosis

  • C9orf72 transcriptional modification

    Boosts normal C9orf72 gene transcription to restore lysosomal function and autophagy.

    Stage not known, Small molecule, C9ORF72

  • RAN-Translation Inhibition

    Inhibits RAN-mediated translation of repeat expansions into toxic dipeptide-repeat proteins.

    Stage not known, Small molecule

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms1
  • Funding rounds and grants1
  • People13
  • Similar companies6

Intelligence